

Other focused conferences during WorldPharma2010

- 1: Clinical pharmacology in emerging and developing countries
- 2: Transmembrane transport: perspectives for disease and drug discovery
- 3: Ion channels in analgesia and anaesthesia
- 4: Pharmacoepidemiology, current controversies and opportunities
- 5: Translational science in the metabolic syndrome: basic and clinical pharmacology
- 6: The heart gone wrong; stabilization of cardiac function
- 8: Developments in the treatment of sexual dysfunction and diseases of the lower urinary tract
- 9: Inflammation and immunopharmacology: new tools for old diseases
- 10: Drugs for half the world: paediatric clinical pharmacology
- 11: G protein-coupled 7TM receptors:
from molecular to physiological function
- 12: Ion channelopathies:
new windows on complex disease and therapy
- 13: Maximising benefits and minimizing harms from drugs
- 14: Addiction and doping:
neurobiological and clinical basis of emerging treatments
- 15: Endothelium in health and disease
- 16: Natural products: past and future?
- 17: New approaches and targets in psychiatry
- 18: Nuclear receptor targets for treatment of diseases

Danish Society for 
Pharmacology



BCPT
Basic & Clinical Pharmacology & Toxicology



Printed in Denmark

Please find further details on www.WorldPharma2010.org



WorldPharma2010

16th World Congress on Basic and Clinical Pharmacology.
July 17-23, 2010, Copenhagen, Denmark

WorldPharma2010 will include a
2-day focused conference on

**Simulation and data
modelling in drug development.
Better drugs faster?**

19-20 July 2010

**Abstract deadline 15 January 2010
Early bird registration deadline 15 March 2010**

Invitation

July 17-23 2010 is the time for a major event for pharmacology, the science of how drugs affect the living organism. Basic and clinical pharmacology, kept separate for too long, have come together again to encompass the whole process of drug development from molecular biology to clinical practice. This remarriage is to be celebrated in Copenhagen; the world's basic and clinical pharmacologists and all those dealing with the development and use of drugs will meet to discuss how we can work together to meet the need for safe and effective medicines at affordable prices.

WorldPharma2010 is organised by the Danish Society for Pharmacology jointly with the British Pharmacological Society under the auspices of the International Union of Basic and Clinical Pharmacology, IUPHAR.

In the scientific programme, there will be plenary lectures, poster sessions, sponsored symposia, workshops, satellite meetings and focused conferences. Each of the 18 focused conferences contains 4 or 5 half-day sessions all belonging to the same theme. Overleaf is the detailed programme for the focused conference entitled:

"Simulation and data modelling in drug development. Better drugs faster?"

The titles of the other focused conferences are listed on the back of the folder.

In each session there will be free communications as well. We promise you a scientifically excellent programme as well as the opportunity to savour the atmosphere of Copenhagen.



Kim Brøsen
President



Michael Mulvany
Secretary General

Congress secretariat

ICS A/S Copenhagen



Strandvejen 169-171 - P.O. Box 41 - DK-2900 Hellerup, Copenhagen - Denmark
Email: WorldPharma2010@ics.dk - Phone: +45 7023 7823 - Fax: +45 7023 7888
www.WorldPharma2010.org

Simulation and data modelling in drug development. Better drugs faster?

Focused conference leader: Hartmut Derendorf

Session 1 Modelling and simulation - how and why?

Chairperson:
E. Mosekilde

- Multiscale modelling of living systems: towards drugs and therapy
E. Mosekilde, Denmark
- Hitting robustness
H. Kitano, Japan - TBC
- Hitting the rythm
A. Goldbeter, Belgium
- Making systems biology drugs work
B. Schoeberl, USA

Session 2 Disease models - using virtual organs and patient populations

Chairpersons:
H. Derendorf & A. Rostami-Hodjegan

- Can we predict pharmacokinetics (PK) in disease populations?
A. Rostami-Hodjegan, UK
- Integrated models for the glucose - insulin system
M. O. Karlsson, Sweden
- Heart modelling in drug development
B. Rodriguez, UK
- From circadian control of PK/PD to personalized cancer chemotherapy
F. Lévi, France

Session 3 Modelling and simulation in clinical drug development

Chairperson:
H. Schäfer

- Modelling and simulation in clinical drug development at Boehringer
H. Schäfer, Germany
- Modelling and simulation in clinical drug development at Bristol-Myers
M. Pfister, USA
- Modelling and simulation in clinical drug development at Pfizer
S. Krishnaswami, USA
- Modelling and simulation in clinical drug development at Lilly
S. Allerheiligen, USA

Session 4 Modelling and simulation - a regulator's view

Chairpersons:
J. V. Gobburu

- Role of modelling and simulation at the FDA
J. V. Gobburu, USA
- Role of modelling and simulation at the EMEA
F. König, UK
- Role of modelling and simulation for drug approval in Asia
Y. Ando, Japan
- Disease modelling from a regulatory view (preliminary title)
S. Jönsson, Sweden